Reuters logo
BRIEF-Mabvax Therapeutics announces FDA authorization to proceed with MVT-1075 in a Phase I clinical trial for the treatment of pancreatic cancer
February 23, 2017 / 2:33 PM / 7 months ago

BRIEF-Mabvax Therapeutics announces FDA authorization to proceed with MVT-1075 in a Phase I clinical trial for the treatment of pancreatic cancer

Feb 23 (Reuters) - MabVax Therapeutics Holdings Inc

* MabVax Therapeutics announces FDA authorization to proceed with MVT-1075 in a Phase I clinical trial for the treatment of pancreatic cancer

* MabVax Therapeutics - plans to initiate trial in patients with recurrent pancreatic cancer, other CA19-9 positive malignancies in first half 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below